Complete Dose Comparison: Making Your Switch Decision
Why Patients Switch: Wegovy Doses Compared to Mounjaro Benefits
When evaluating Wegovy doses compared to Mounjaro, patients often discover compelling reasons to make the switch. Wegovy (semaglutide) operates as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) functions as a dual GIP/GLP-1 agonist, creating different side effect profiles and dosing experiences. Many patients find Wegovy's established dose escalation schedule more predictable, progressing from 0.25mg through to 2.4mg maintenance over 16 weeks. The medication has demonstrated consistent results in the STEP trial programme, with patients achieving significant weight management alongside reduced-calorie diets and increased physical activity.
Cost considerations frequently drive switching decisions, particularly for long-term maintenance therapy. Wegovy's pricing structure at EverydayMeds offers transparent monthly costs, with the 2.4mg maintenance dose available for £209.99. Our bundle options provide additional convenience for patients requiring consistent supply, eliminating the uncertainty of monthly reordering. Storage advantages also influence patient choice, as Wegovy maintains stability for 6 weeks at room temperature compared to Mounjaro's 21-day limit, offering greater flexibility for travel and daily routine management.
Pricing Comparison: Wegovy Doses Compared to Mounjaro Costs
Understanding the true cost implications when comparing Wegovy doses to Mounjaro requires examining both initiation and maintenance phases. Wegovy's dose escalation begins at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), reaching £209.99 for the 2.4mg maintenance dose. New customers benefit from discount code FIRST40, whilst returning customers use DOSE25, with both codes applied at checkout to reach these final prices. This transparent pricing structure allows accurate monthly budgeting throughout your weight management journey.
Bundle options provide additional value for patients committed to consistent therapy. Our Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, covering the first three months of treatment, whilst the Ultimate Stability Trio offers three months of 2.4mg maintenance for £649.99. These bundles eliminate the risk of supply interruptions and reduce ordering frequency. Both Wegovy and Mounjaro are available through EverydayMeds with identical service standards, allowing seamless transitions under prescriber guidance without changing pharmacy providers or compromising on delivery reliability.
Clinical Evidence: Wegovy Doses Compared to Mounjaro Research
The STEP clinical trial programme provides robust evidence for Wegovy's efficacy across its dose range. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 demonstrated effectiveness in patients with type 2 diabetes, achieving 9.6% average weight loss, whilst STEP 5 confirmed sustained results of 15.2% at two years.
When comparing clinical outcomes, both Wegovy and Mounjaro have demonstrated significant efficacy in their respective trials, though direct head-to-head comparisons require careful interpretation due to different trial designs and patient populations. The SELECT cardiovascular outcomes trial showed Wegovy reduced major adverse cardiovascular events by 20%, adding an important safety dimension to treatment considerations for eligible patients.
Mechanism Differences: How Wegovy Doses Work Compared to Mounjaro
Wegovy operates specifically as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and glucose metabolism. This targeted approach reduces appetite, promotes satiety after smaller meals, and may diminish food cravings by acting on brain appetite centres. The once-weekly injection provides consistent hormone levels, supporting sustainable eating pattern changes when combined with lifestyle modifications. Unlike dual-mechanism treatments, Wegovy's singular GLP-1 focus offers a well-understood pathway with extensive clinical experience since its approval for weight management.
Ordering Process: Switching to Wegovy Through EverydayMeds
Making the switch to Wegovy begins with our streamlined 3-minute online clinical assessment, designed specifically for patients transitioning between GLP-1 medications. Our prescribers, working within our GPhC-registered pharmacy (#9012878), review your medical history and current medication experience to ensure safe transitioning. Standard prescriber review takes 3 working days, with express 24-hour review available for urgent requirements. Once approved, your Wegovy prescription ships via next-day delivery in temperature-controlled packaging, maintaining the cold-chain integrity essential for medication efficacy. This process ensures continuity of care whilst transitioning between treatments.
Storage and Practical Considerations: Wegovy Doses Compared to Mounjaro
Wegovy's storage requirements offer practical advantages for many patients switching from alternative GLP-1 treatments. The FlexTouch pre-filled pen requires refrigeration at 2-8°C before first use but maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration. This extended room temperature stability surpasses many competing medications, providing flexibility for work travel, holidays, or irregular schedules. The dose escalation protocol is mandatory and cannot be accelerated, ensuring optimal tolerance whilst achieving therapeutic benefits through the structured 16-week titration to 2.4mg maintenance dosing.
Switching Strategies: Transitioning From Mounjaro to Wegovy Doses
Patients considering switching from Mounjaro to Wegovy require careful transition planning under prescriber supervision. The different receptor mechanisms mean dose equivalency isn't directly comparable, with most prescribers recommending standard Wegovy initiation protocols regardless of previous GLP-1 experience. This approach minimises side effects and allows proper tolerance assessment with the new medication. Timing the switch often depends on supply considerations, cost factors, or side effect management, with many patients choosing transition points that align with their current medication's natural pause points.
EverydayMeds stocks both medications with identical service standards, eliminating pharmacy-related barriers to switching. Our clinical team coordinates with your prescriber to ensure seamless transitions, maintaining your weight management momentum throughout the changeover period. The consistent delivery schedule and temperature-controlled shipping apply to both medications, providing reliability regardless of your final choice.
Purchase Wegovy: Complete Your Switch Through EverydayMeds
Ready to explore switching to Wegovy? Our complete service begins with clinical assessment and extends through ongoing prescription management with reliable UK delivery. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to access our competitive pricing structure. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your assessment, with expert prescriber guidance ensuring your switch optimises both clinical outcomes and cost-effectiveness. Our GPhC-registered pharmacy (#9012878) maintains the highest standards for prescription-only medicine dispensing, supporting your long-term weight management success through every stage of treatment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
